B Cell News and Research

RSS

CAR-T cell therapy shows promise for treating rheumatoid arthritis

Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.

3 Jun 2026

Higher-dose ocrelizumab depletes more B cells but does not slow MS progression

Higher-dose ocrelizumab produced greater peripheral B-cell depletion than the approved 600 mg regimen in two phase 3b trials of relapsing and primary progressive multiple sclerosis. However, the higher doses did not significantly delay disability progression, supporting the 600 mg dose as the current standard regimen with a favorable benefit-risk profile.

31 May 2026

From killers to strategists: CAR T cells enter their multifunctional era

A review of 1,801 registered CAR T clinical trials shows that multifunctional designs now account for 533 trials and 33% of new CAR T products submitted for clinical testing in 2025. The field is shifting toward multitargeted, safety-controlled, cytokine-secreting, and checkpoint-modulating CAR T cells, but manufacturing, regulation, and limited clinical outcome data remain key barriers.

30 Apr 2026

New map reveals B cell clusters linked to faster diabetic kidney disease

A detailed new map of the human kidney revealed a previously unrecognized form of diabetic kidney disease (DKD) marked by clusters of immune cells-specifically B cells-that are linked to faster disease progression.

29 Apr 2026

Obesity may leave immune cells stuck in inflammatory mode after weight loss

A new EMBO Reports study suggests that obesity can leave a lasting epigenetic imprint on CD4 T cells, delaying the restoration of adaptive immune balance after weight loss. Using mouse models and human cohorts, researchers linked this immune “memory” to DNA methylation changes, saturated fatty acids, autophagy, and immune senescence.

28 Apr 2026

Study reframes Hodgkin lymphoma as a cancer of failed cell development

For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an "identity crisis."

24 Apr 2026

Researchers identify molecular link between autoimmune disease and lymphoma risk

Patients with autoimmune diseases such as lupus and rheumatoid arthritis have an increased risk of developing lymphoma, a form of blood cancer that affects the lymphatic system.

13 Apr 2026

FDA clears investigational new drug application to test sCAR-T therapy for autoimmune conditions

Calibr-Skaggs Institute for Innovative Medicines, the drug discovery division of Scripps Research, announced today that the FDA has cleared their investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions.

10 Apr 2026

Gut-derived metabolites regulate immune cells in complex ways

Published on March 23, 2026, in Volume 2, article number 18 of the journal Immunity & Inflammation, the review begins by systematically outlining the sources and synthetic pathways of immune-relevant microbial metabolites, including bile acids, short-chain fatty acids, amino acid derivatives, vitamins, trimethylamine/trimethylamine N-oxide, and odd-chain fatty acids.

31 Mar 2026

Study reveals how inflammation disrupts lymph node structure in lymphoma

In aggressive lymphomas, inflammatory messengers reprogram the "conductors" of the immune system, causing lymph nodes structure to collapse.

26 Mar 2026

Early blood test could guide personalized lymphoma treatment decisions

Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of treatment: an antibody designed to wipe out cancerous B cells plus a combination of four chemotherapy drugs.

25 Mar 2026

Innovative platform detects diseases using a single drop of blood

An innovative platform developed by PKU researchers called "cf-EpiTracing" has proved capable of detecting and tracing diseases from as little as 50 μl of human plasma, or roughly a drop of blood.

16 Mar 2026

New insights highlight multifaceted roles of CD4+ T cells in tumor immunity

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell killing.

13 Mar 2026

Prior flu exposure may weaken the immune response to other strains

Prior exposure to one strain of influenza virus may weaken children's ability to mount an effective antibody response against their subsequent exposure to a different flu strain, according to a study led by Weill Cornell Medicine investigators.

11 Mar 2026

DNA origami vaccine platform shows promise against multiple infectious viruses

The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical trial stages, the first COVID-19 mRNA vaccine was administered on 8 December 2020 and mathematical models suggest that mRNA vaccines prevented at least 14.4 million deaths from COVID-19 in the first year alone.

11 Mar 2026

Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation

Intranasal boosting after prior intramuscular COVID vaccination induced strong mucosal IgA responses in a small human cohort. These antibodies showed markedly enhanced neutralising activity against Omicron variants and evidence of immune memory reprogramming toward mucosal protection.

15 Feb 2026

Gut microbial butyrate enhances mucosal vaccine antibody responses

A research team from POSTECH and ImmunoBiome in Korea, led by Professor Sin-Hyeog Im, has uncovered a new mechanism showing how butyrate-a short-chain fatty acid produced by gut commensal bacteria-enhances T follicular helper (Tfh) cell activity to promote antibody production and strengthen mucosal vaccine efficacy.

4 Feb 2026